Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Duration of Major Molecular Response and Discontinuation in Deep Molecular Response (MR4.5) Were Associated with Longer Treatment-Free Survival after Imatinib Discontinuation - Results from Two Prospective Brazilian Trials

Katia B Pagnano, MD PhD, Fernanda S Seguro, MD, Eliana C Miranda, PhD, Ana Beatriz Pascoal Lopes, Andre Abdo, MD, Marcia Torresan Delamain, MD, Thales Pereira, MD, Gislaine Borba Duarte, MD, Fernanda Maria Santos, Jessica CN Vianna, Matheus Sebastian Da Silva, Luciana Nardinelli, M.Sc, Valquiria Povoa, Graziele Pavan, Bruna R Vergilio, Vanderson Rocha, MD PhD, Carmino Antonio Souza, MD PhD, Erich V De Paula, MD PhD, Israel Bendit, MD PhD

Blood (2019) 134 (Supplement_1): 1655.

https://doi.org/10.1182/blood-2019-125368

Published: 2019

Journal Articles

Pioglitazone Did Not Affect PPAR-Γ , STAT5 , HIF2α and CITED2 Gene Expression in Chronic Myeloid Leukemia Patients with Deep Molecular Response

Ana Beatriz Pascoal Lopes, Eliana C Miranda, PhD, Valquíria Mariane Oliveira Póvoa, Bruna Rocha Vergílio, Graziele Cristina Pavan Furlin, Marcia Torresan Delamain, MD, Gislaine Borba Duarte, MD, Carmino Antonio Souza, MD PhD, Erich V De Paula, MD PhD, Katia B Pagnano, MD PhD

Blood (2019) 134 (Supplement_1): 1637.

https://doi.org/10.1182/blood-2019-128265

Published: 2019

Journal Articles

Low-Dose Azacitidine, Pioglitazone and All-Trans Retinoic Acid Versus Standard-Dose Azacitidine in Patients ≥ 60 Years with Acute Myeloid Leukemia Refractory to Standard Induction Chemotherapy (AMLSG 26-16/AML-ViVA): Results of the Safety Run-in Phase I

Daniel Heudobler, Sebastian Klobuch, MD, Florian Lüke, MD, Joachim Hahn, MD, Matthias Grube, MD, Stephan Kremers, MD, Thomas Südhoff, MD, Jörg Westermann, MD, Marie-Luise Huetter-Kroenke, MD, Peter Paschka, MD, Gauthier Bouche, Hartmut Döhner, MD, Wolfgang Herr, MD, Simone Thomas, MD, Albrecht Reichle, MD

Blood (2019) 134 (Supplement_1): 1382.

https://doi.org/10.1182/blood-2019-129977

Published: 2019

Journal Articles

Peroxisome Proliferator-Activated Receptors: Targets for the Treatment of Philadelphia Chromosome-Positive Leukemia Cells

Seiichi Okabe, MD PhD, Tetsuzo Tauchi, MD, Yuko Tanaka, MD PhD, Kazuma Ohyashiki, MD PhD

Blood (2017) 130 (Supplement 1): 5241.

https://doi.org/10.1182/blood.V130.Suppl_1.5241.5241

Published: 2017

Journal Articles

Pilot Study of Imatinib Discontinuation in Patients with Chronic Myeloid Leukemia with Deep Molecular Response (EDI-PIO) — Evaluation of Pioglitazone in Treatment-Free Remission

Katia B Pagnano, MD, Eliana C Miranda, Marcia Torresan Delamain, Gislaine Oliveira Duarte, MD, Bruna Virgilio, Jessica Vianna, Erich Vinicius De Paula, MD PhD, Carmino Antonio De Souza, MD PhD

Blood (2017) 130 (Supplement 1): 1595.

https://doi.org/10.1182/blood.V130.Suppl_1.1595.1595

Published: 2017

Journal Articles

Activation of PPARγ by endogenous prostaglandin J 2 mediates the antileukemic effect of selenium in murine leukemia

Emily R. Finch, Diwakar B. Tukaramrao, Laura L. Goodfield, Michael D. Quickel, Robert F. Paulson, K. Sandeep Prabhu

Blood (2017) 129 (13): 1802–1810.

https://doi.org/10.1182/blood-2016-08-736405

Published: 2017

Includes: Supplemental data

Journal Articles

Ponatinib and Cardiovascular Complications

Alvin H. Schmaier, MD, Alona A. Merkulova, M.S., Steven Mitchell, Evi X Stavrou, MD

Blood (2016) 128 (22): 3055.

https://doi.org/10.1182/blood.V128.22.3055.3055

Published: 2016

Journal Articles

Biomodulatory Metronomic Therapy Shows Remarkable Activity in Chemorefractory Multi-System Langerhans Cell Histiocytosis

Daniel Heudobler, MD, Klaus Rehe, MD PhD, Juergen Foell, MD, Selim Corbacioglu, MD, Gerhard Hildebrandt, MD, Wolfgang Herr, MD, Albrecht Reichle, MD, Martin Vogelhuber, MD

Blood (2016) 128 (22): 4254.

https://doi.org/10.1182/blood.V128.22.4254.4254

Published: 2016

Journal Articles

Long-Term Treatment with Rosiglitazone Delays Hematopoietic Recovery in Response to Stress

Wenyi Lu, Kaiyan Liu, Weimin Wang, Shujuan Wang, Yonghuai Feng

Blood (2015) 126 (23): 4769.

https://doi.org/10.1182/blood.V126.23.4769.4769

Published: 2015

Journal Articles

Erosion Of The Chronic Myeloid Leukemia Stem Cell Pool By PPARγ Agonists

Stephane Prost, Francis Relouzat, Marc Spenchian, Gérald Massonnet, Jean-Paul Beressi, Els Verhoeyen, Benjamin Maneglier, Sylvie Castaigne, Christine Chomienne, Stany Chretien, Philippe Rousselot, Philippe Leboulch, PhD

Blood (2013) 122 (21): 5197.

https://doi.org/10.1182/blood.V122.21.5197.5197

Published: 2013

Journal Articles

Targeting STAT5 Expression Resulted in Molecular Response Improvement in Patients with Chronic Phase CML Treated with Imatinib

Philippe Rousselot, MD, PhD, Lydia Roy, MD, Gabriel Etienne, MD, PHD, Laurence Legros, MD, PhD, Aude Charbonnier, MD, PhD, Valérie Coiteux, MD, Pascale Cony-Makhoul, MD, Francois-Xavier Mahon, MD, PhD, Joelle Guilhot, PhD, Jean-Michel Cayuela, Francis Relouzat, Philippe Leboulche, Stephane Prost

Blood (2012) 120 (21): 696.

https://doi.org/10.1182/blood.V120.21.696.696

Published: 2012

Journal Articles

Anti-Inflammatory, Immuno-Modulatory and Angiostatic Treatment As Third-Line Therapy for Multiple Myeloma (MM) – a Combined Treatment Setting of Lenalidomide with Pioglitazone, Dexamethasone and Low-Dose Treosulfan (phase I/II)

Albrecht Reichle, Christina Hart, Matthias Grube, Reinhard Andreesen

Blood (2012) 120 (21): 5029.

https://doi.org/10.1182/blood.V120.21.5029.5029

Published: 2012

Journal Articles

Pioglitazone Inhibits Platelet Function and Potentiates the Effects of Aspirin

John P. Mongan, DO, Hanna Mieszczanska, MD, Richard P. Phipps, PhD, Charles W. Francis, MD

Blood (2011) 118 (21): 1228.

https://doi.org/10.1182/blood.V118.21.1228.1228

Published: 2011

Journal Articles

PPARγ activation normalizes resolution of acute sterile inflammation in murine chronic granulomatous disease

Ruby Fernandez-Boyanapalli, S. Courtney Frasch, David W. H. Riches, R. William Vandivier, Peter M. Henson, Donna L. Bratton

Blood (2010) 116 (22): 4512–4522.

https://doi.org/10.1182/blood-2010-02-272005

Published: 2010

Includes: Supplemental data

Journal Articles

Compassionate Use of Combined Anti-Inflammatory and Angiostatic Treatment as Third-Line Therapy in Eight Patients with Multiple Myeloma – a Combined Treatment Setting of Lenalidomide with Pioglitazone, Dexamethasone and Low-Dose Treosulfan.

Albrecht Reichle, Martin Vogelhuber, Ernst Holler, PhD, Joachim Hahn, Reinhard Andreesen, MD, PhD

Blood (2009) 114 (22): 4958.

https://doi.org/10.1182/blood.V114.22.4958.4958

Published: 2009

Journal Articles

Cotreatment with Pioglitazone, a Synthetic Ligand for Peroxisome Proliferator-Activated Receptor γ (PPARγ), Enhances Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL)-Induced Apoptosis of Human Leukemia Cells.

Joo-In Park, M.D. Ph.D., Hoon Han, Ji-Seon Han, Hyuk-Chan Kwon, M.D., Ph.D., Jin-Yeong Han, M.D., Ph.D., Jin-Sook Jeong, M.D., Ph.D., Yoe-Sik Bae, Ph.D., Jong-Young Kwak, M.D., Ph.D.

Blood (2004) 104 (11): 4377.

https://doi.org/10.1182/blood.V104.11.4377.4377

Published: 2004

Journal Articles

Pioglitazone Inhibits the Growth of Human Leukemic Cell Lines and Primary Leukemic Cells in Vitro.

Yoshihiro Hatta, MD, Minoru Saiki, MD, Yuko Enomoto, Shin Aizawa, MD, Umihiko Sawada, MD, Takashi Horie, MD

Blood (2004) 104 (11): 4493.

https://doi.org/10.1182/blood.V104.11.4493.4493

Published: 2004

Journal Articles

Induction of Apoptosis in Multiple Myeloma by Ligands of Peroxisome Proliferator-Activated Receptor γ (PPAR-γ).

Jan Eucker, MD, Katharina Baengeroth, Ivana Zavrski, MD, Holger Krebbel, Chuanbing Zang, PhD, Ulrike Heider, MD, Christian Jakob, MD, Elena Elstner, PhD, Kurt Possinger, MD, Orhan Sezer, MD

Blood (2004) 104 (11): 4848.

https://doi.org/10.1182/blood.V104.11.4848.4848

Published: 2004

Journal Articles

Induction of Growth Inhibition and Apoptosis by TZD18, a Novel Dual Ligand for PPAR alpha/gamma, in Human Ph-Positive ALL Cells In Vitro .

Elena Elstner, PhD, Hongyu Liu, MS, Chuanbing Zang, PhD, Dachuan Liu, MS, Shunnan Xu, Martin H. Fenner, MD, Kurt Possinger, MD

Blood (2004) 104 (11): 2088.

https://doi.org/10.1182/blood.V104.11.2088.2088

Published: 2004

Journal Articles

A Role for Adipocyte-Enriched Transcription Factor, PPAR-γ, in Up-Regulation of PAI-1 Gene Expression during Adipogenesis.

Hayato Ihara, Ph.D., David J. Loskutoff, Ph.D., Tetsumei Urano, M.D., Ph.D.

Blood (2004) 104 (11): 1940.

https://doi.org/10.1182/blood.V104.11.1940.1940

Published: 2004

NARROW

Duration of Major Molecular Response and Discontinuation in Deep Molecular Response (MR4.5) Were Associated with Longer Treatment-Free Survival after Imatinib Discontinuation - Results from Two Prospective Brazilian Trials

Pioglitazone Did Not Affect PPAR-Γ , STAT5 , HIF2α and CITED2 Gene Expression in Chronic Myeloid Leukemia Patients with Deep Molecular Response

Low-Dose Azacitidine, Pioglitazone and All-Trans Retinoic Acid Versus Standard-Dose Azacitidine in Patients ≥ 60 Years with Acute Myeloid Leukemia Refractory to Standard Induction Chemotherapy (AMLSG 26-16/AML-ViVA): Results of the Safety Run-in Phase I

Peroxisome Proliferator-Activated Receptors: Targets for the Treatment of Philadelphia Chromosome-Positive Leukemia Cells

Pilot Study of Imatinib Discontinuation in Patients with Chronic Myeloid Leukemia with Deep Molecular Response (EDI-PIO) — Evaluation of Pioglitazone in Treatment-Free Remission

Activation of PPARγ by endogenous prostaglandin J 2 mediates the antileukemic effect of selenium in murine leukemia

Ponatinib and Cardiovascular Complications

Biomodulatory Metronomic Therapy Shows Remarkable Activity in Chemorefractory Multi-System Langerhans Cell Histiocytosis

Long-Term Treatment with Rosiglitazone Delays Hematopoietic Recovery in Response to Stress

Erosion Of The Chronic Myeloid Leukemia Stem Cell Pool By PPARγ Agonists

Targeting STAT5 Expression Resulted in Molecular Response Improvement in Patients with Chronic Phase CML Treated with Imatinib

Anti-Inflammatory, Immuno-Modulatory and Angiostatic Treatment As Third-Line Therapy for Multiple Myeloma (MM) – a Combined Treatment Setting of Lenalidomide with Pioglitazone, Dexamethasone and Low-Dose Treosulfan (phase I/II)

Pioglitazone Inhibits Platelet Function and Potentiates the Effects of Aspirin

PPARγ activation normalizes resolution of acute sterile inflammation in murine chronic granulomatous disease

Compassionate Use of Combined Anti-Inflammatory and Angiostatic Treatment as Third-Line Therapy in Eight Patients with Multiple Myeloma – a Combined Treatment Setting of Lenalidomide with Pioglitazone, Dexamethasone and Low-Dose Treosulfan.

Cotreatment with Pioglitazone, a Synthetic Ligand for Peroxisome Proliferator-Activated Receptor γ (PPARγ), Enhances Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL)-Induced Apoptosis of Human Leukemia Cells.

Pioglitazone Inhibits the Growth of Human Leukemic Cell Lines and Primary Leukemic Cells in Vitro.

Induction of Apoptosis in Multiple Myeloma by Ligands of Peroxisome Proliferator-Activated Receptor γ (PPAR-γ).

Induction of Growth Inhibition and Apoptosis by TZD18, a Novel Dual Ligand for PPAR alpha/gamma, in Human Ph-Positive ALL Cells In Vitro .

A Role for Adipocyte-Enriched Transcription Factor, PPAR-γ, in Up-Regulation of PAI-1 Gene Expression during Adipogenesis.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only